Clinical trials
Phase 2 trials in Serbia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
343 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 10 |
| 2007 | 13 |
| 2008 | 15 |
| 2009 | 17 |
| 2010 | 14 |
| 2011 | 10 |
| 2012 | 14 |
| 2013 | 17 |
| 2014 | 9 |
| 2015 | 16 |
| 2016 | 23 |
| 2017 | 21 |
| 2018 | 15 |
| 2019 | 19 |
| 2020 | 18 |
| 2021 | 21 |
| 2022 | 17 |
| 2023 | 9 |
| 2024 | 20 |
| 2025 | 22 |
| 2026 | 16 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 210 |
| Terminated | 55 |
| Recruiting | 39 |
| Active, not recruiting | 30 |
| Unknown status | 5 |
| Withdrawn | 2 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 17 |
| Pfizer | 15 |
| AbbVie | 10 |
| Novo Nordisk A/S | 10 |
| AstraZeneca | 7 |
| Genentech, Inc. | 7 |
| Amgen | 6 |
| Ablynx, a Sanofi company | 5 |
| Biogen | 5 |
| Actelion | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 38 |
| Colitis, Ulcerative | 32 |
| Inflammatory Bowel Diseases | 15 |
| Lupus Erythematosus, Systemic | 11 |
| Multiple Sclerosis | 10 |
| Asthma | 9 |
| Crohn Disease | 9 |
| Acromegaly | 8 |
| Breast Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 8 |
Trials
Showing 51 to 75 of 343. Each trial links to its page on Pharma Observatory.
243 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.